Mubadala Health

What Mubadala Health does

Mubadala Health, operating commercially as M42, is a tech-enabled health company headquartered in Abu Dhabi, UAE, founded in 2021. It operates four integrated platforms — Global Patient Care, Digital Health Solutions, Integrated Health Solutions, and AI Life Sciences — supported by specialized sub-brands including IROS (genomics-driven clinical trials), Abu Dhabi Biobank, National Reference Laboratory (NRL), and Amana Healthcare Bahrain. The company runs 480 facilities across 27 countries, employs approximately 20,000 people, and serves 15 million patients annually across 100+ service lines. It is positioned as the No. 1 largest healthcare company in the Middle East and the #3 largest dialysis provider globally, and operates the first centralized Health Information Exchange in the region.

Core technology is built around the integration of genomics, digital health, and AI. Proprietary or partner-enabled capabilities include the Emirati Genome Programme integration, the Abu Dhabi Biobank, Human Virtual Twin simulation technology (with BioTwin), AI-powered digital pathology and prostate cancer diagnostics (with Qritive), and a centralized health information exchange enabling cross-provider data sharing. These support precision medicine, early disease identification, drug discovery, and population-scale health management.

The revenue model combines healthcare service delivery (multi-specialty clinical care, dialysis, diagnostics through NRL, and population health programs under Integrated Health Solutions) with digital health solutions offered to providers and institutions. Go-to-market relies on direct facility operations, enterprise partnerships with government health authorities and research institutions, and channel partnerships with technology vendors. Pricing is contract-negotiated with government, institutional, and insurance counterparties rather than publicly disclosed.

Name

Mubadala Health

Legal name

M42

Website

https://mubadalahealth.ae

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Mubadala Health (operating as M42) is an Abu Dhabi-based tech-enabled health company operating 480 facilities across 27 countries, serving 15 million patients annually through integrated clinical care, genomics, AI diagnostics, and digital health platforms.

Ownership category

akta.pro rank

Product category

Integrated Healthcare Services

NAICS

General Medical and Surgical Hospitals (6221), Ambulatory Health Care Services (621), Medical and Diagnostic Laboratories (6215)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071), Services-Hospitals (8060)

akta.pro primary industry

Healthcare On‑Demand Platforms (Telehealth, Home Care, Nursing) (BPAMAHAH)

akta.pro secondary industry

Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways) (HLACAFAO)

Keywords

• Healthcare services
• Digital health solutions
• Diagnostic services
• Genomic medicine
• Integrated healthcare

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Healthcare Services Revenue: Revenue generated from providing medical services through 480 clinics and facilities across 27 countries, serving approximately 15 million patients annually. Includes diagnostic services, dialysis treatments, and general healthcare services.
2. Digital Health Solutions: Revenue from scaling AI-driven innovations and digital health technologies to healthcare providers and institutions worldwide, including pathology diagnostics and health information systems.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Mubadala Health operates an integrated tech-enabled healthcare platform through M42, providing medical services across 480 facilities in 27 countries serving 15 million patients annually. The company delivers care through four platforms: Global Patient Care (clinical services across 100+ service lines), Digital Health Solutions (AI-driven healthcare technology), Integrated Health Solutions (population health programs), and AI Life Sciences (drug discovery). It also operates diagnostic services through National Reference Laboratory and genomics initiatives via IROS and Abu Dhabi Biobank.

Product overview

M42 operates as a tech-enabled health company offering four integrated platform services: Global Patient Care (operates 480 clinics across 27 countries serving 15 million patients annually), Digital Health Solutions (AI-driven digital health innovations), Integrated Health Solutions (population health and national programs), and AI Life Sciences (AI-powered drug discovery and space health). Supporting these platforms are specialized sub-brands including IROS (genomics-driven clinical trials) and the National Reference Laboratory (diagnostic services with AI-powered pathology). The company positions itself as the #1 largest healthcare company in the Middle East and #3 largest dialysis provider globally.

Differentiator

Problem solved

Functional benefit

Brands

• Global Patient Care: Leading healthcare organization integrating UAE and international assets, operating 480 clinics across 27 countries, serving 15 million patients annually.
• Digital Health Solutions
• Integrated Health Solutions
• AI Life Sciences
• IROS
• Abu Dhabi Biobank
• National Reference Laboratory (NRL)
• Amana Healthcare Bahrain

Products and services

• Global Patient Care

Quantifiable outcome

• 15 million patients served annually
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• Department of Health – Abu DhabiflagshipStrategic or Co-development Partner · 29 June 2026Collaboration on Emirati Genome Programme to enable the UAE's first genomics-driven clinical trial for Alzheimer's prevention. The partnership leverages population genomic data for early identification and disease prevention, advancing precision medicine initiatives in the UAE.
• BioTwincoreStrategic or Co-development Partner · 26 June 2026Strategic partnership between Abu Dhabi Biobank and BioTwin to expand Human Virtual Twin technology in the UAE. This collaboration supports advanced simulation capabilities for personalized medicine and drug testing using virtual human biology models.
• RCSI Bahrain (Royal College of Surgeons in Ireland - Bahrain)coreStrategic or Co-development Partner · 17 June 2026MOU between Amana Healthcare Bahrain and RCSI Bahrain to support Bahrain's specialist healthcare through expanded clinical training and research pathways. Medical students gain access to real-world care environments at Amana Healthcare facilities.
• QritivecoreTechnology or Integration · 8 June 2026National Reference Laboratory (NRL), part of M42, collaborated with Qritive (digital pathology innovator) to introduce UAE breakthrough in AI-powered prostate cancer diagnostics, enhancing diagnostic accuracy and speed.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/MubadalaHealth
• Facebookfacebook.com/mubadalahealth

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mubadala Health